Personalized ctDNA micro-panels can monitor and predict clinical outcomes for patients with triple-negative breast cancer.

ABSTRACT: Circulating tumor DNA (ctDNA) in peripheral blood has been used to predict prognosis and therapeutic response for triple-negative breast cancer (TNBC) patients. However, previous approaches typically use large comprehensive panels of genes commonly mutated across all breast cancers. Given the reduction in sequencing costs and decreased turnaround times associated with panel generation, the objective of this study was to assess the use of custom micro-panels for tracking disease and predicting clinical outcomes for patients with TNBC. Paired tumor-normal samples from patients with TNBC were obtained at diagnosis (T0) and whole exome sequencing (WES) was performed to identify somatic variants associated with individual tumors. Custom micro-panels of 4-6 variants were created for each individ

SUBMITTER: Barnell EK 

PROVIDER: S-EPMC9588015 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature